Meeder Asset Management Inc Denali Therapeutics Inc. Transaction History

Meeder Asset Management Inc

  • $1.48 Billion
  • Q3 2024

A detailed history of Meeder Asset Management Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Meeder Asset Management Inc holds 159 shares of DNLI stock, worth $3,844. This represents 0.0% of its overall portfolio holdings.

Number of Shares
159
Holding current value
$3,844
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024
BUY
$20.96 - $31.05 $3,332 - $4,936
159 New
159 $4,000
Q4 2021

Feb 11, 2022
SELL
$42.59 - $55.02 $156,262 - $201,868
-3,669 Closed
0 $0
Q3 2021

Nov 08, 2021
BUY
$48.48 - $78.23 $44,698 - $72,128
922 Added 33.56%
3,669 $186,000
Q2 2021

Aug 09, 2021
BUY
$50.3 - $78.44 $15,391 - $24,002
306 Added 12.54%
2,747 $215,000
Q1 2021

Apr 28, 2021
BUY
$53.8 - $81.53 $131,325 - $199,014
2,441 New
2,441 $139,000
Q4 2020

Feb 09, 2021
SELL
$36.89 - $93.56 $89,495 - $226,976
-2,426 Closed
0 $0
Q3 2020

Nov 02, 2020
BUY
$23.13 - $38.84 $45,334 - $76,126
1,960 Added 420.6%
2,426 $88,000
Q2 2020

Aug 11, 2020
SELL
$16.01 - $28.82 $16,762 - $30,174
-1,047 Reduced 69.2%
466 $13,000
Q1 2020

May 15, 2020
BUY
$14.2 - $27.98 $21,484 - $42,333
1,513 New
1,513 $26,000
Q1 2019

Apr 16, 2019
SELL
$17.99 - $24.65 $5,720 - $7,838
-318 Closed
0 $0
Q4 2018

Jan 17, 2019
SELL
$13.88 - $21.75 $1,096 - $1,718
-79 Reduced 19.9%
318 $7,000
Q3 2018

Nov 02, 2018
BUY
$12.46 - $21.74 $4,946 - $8,630
397 New
397 $0

Others Institutions Holding DNLI

# of Institutions
228
Shares Held
120M
Call Options Held
60.6K
Put Options Held
48.4K
View Full List

About Denali Therapeutics Inc.

DNLI Quotes by TradingView
  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.24B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email